377 related articles for article (PubMed ID: 30197512)
21. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
[TBL] [Abstract][Full Text] [Related]
22. Characteristics of newly diagnosed COPD patients treated with triple inhaled therapy by general practitioners: a real world Italian study.
Di Marco F; Santus P; Terraneo S; Peruzzi E; Muscianisi E; Ripellino C; Pegoraro V
NPJ Prim Care Respir Med; 2017 Sep; 27(1):51. PubMed ID: 28883469
[TBL] [Abstract][Full Text] [Related]
23. A Real World Study to Assess the Effectiveness of Switching to Once Daily Closed Triple Therapy from Mono/Dual Combination or Open Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease.
Huang WC; Chen CY; Liao WC; Wu BR; Chen WC; Tu CY; Chen CH; Cheng WC
Int J Chron Obstruct Pulmon Dis; 2021; 16():1555-1568. PubMed ID: 34113089
[TBL] [Abstract][Full Text] [Related]
24. [Medication management of COPD].
Gueçamburu M; Zysman M
Rev Prat; 2024 Jan; 74(1):7-12. PubMed ID: 38329243
[TBL] [Abstract][Full Text] [Related]
25. Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.
Di Marco F; Santus P; Scichilone N; Solidoro P; Contoli M; Braido F; Corsico AG
Respir Med; 2017 Apr; 125():49-56. PubMed ID: 28340862
[TBL] [Abstract][Full Text] [Related]
26. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI
Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384
[TBL] [Abstract][Full Text] [Related]
27. Significance of Medication History at the Time of Entry into the COPDGene Study: Relationship with Exacerbation and CT Metrics.
Park SJ; Make B; Hersh CP; Bowler RP
COPD; 2015 Aug; 12(4):366-73. PubMed ID: 25254928
[TBL] [Abstract][Full Text] [Related]
28. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
[TBL] [Abstract][Full Text] [Related]
29. When is dual bronchodilation indicated in COPD?
Thomas M; Halpin DM; Miravitlles M
Int J Chron Obstruct Pulmon Dis; 2017; 12():2291-2305. PubMed ID: 28814857
[TBL] [Abstract][Full Text] [Related]
30. PRIMUS - Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation.
Tkacz J; Evans KA; Touchette DR; Portillo E; Strange C; Staresinic A; Feigler N; Patel S; Pollack M
Int J Chron Obstruct Pulmon Dis; 2022; 17():329-342. PubMed ID: 35177901
[TBL] [Abstract][Full Text] [Related]
31. "Real-life" inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD.
Vogelmeier C; Worth H; Buhl R; Criée CP; Lossi NS; Mailänder C; Kardos P
Int J Chron Obstruct Pulmon Dis; 2017; 12():487-494. PubMed ID: 28203072
[TBL] [Abstract][Full Text] [Related]
32. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
Hizawa N
Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
[TBL] [Abstract][Full Text] [Related]
33. In 'real world' patients with COPD, exacerbation history, and not blood eosinophils, is the most reliable predictor of future exacerbations.
Worth H; Buhl R; Criée CP; Kardos P; Gückel E; Vogelmeier CF
Respir Res; 2023 Jan; 24(1):2. PubMed ID: 36604646
[TBL] [Abstract][Full Text] [Related]
34. Triple combinations in chronic obstructive pulmonary disease - is three better than two?
Cazzola M; Matera MG
Expert Opin Pharmacother; 2014 Dec; 15(17):2475-8. PubMed ID: 25327264
[TBL] [Abstract][Full Text] [Related]
35. Dual Bronchodilator in the Era of Triple Therapy.
Papaioannou AI; Loukides S; Bakakos P; Kosmas EN; Rovina N; Steiropoulos P; Fouka E; Hillas G; Patentalakis G; Kouvela M; Tzanakis N
Int J Chron Obstruct Pulmon Dis; 2020; 15():2695-2705. PubMed ID: 33149567
[TBL] [Abstract][Full Text] [Related]
36. A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD.
Calzetta L; Rogliani P; Matera MG; Cazzola M
Chest; 2016 May; 149(5):1181-96. PubMed ID: 26923629
[TBL] [Abstract][Full Text] [Related]
37. [Current position of new fixed-dose combination of tiotropium and olodaterol - its role in the treatment of chronic obstructive pulmonary disease in the Czech Republic].
Koblížek V; Svoboda M
Vnitr Lek; 2016; 62(12):1011-1020. PubMed ID: 28139131
[TBL] [Abstract][Full Text] [Related]
38. Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.
Rossi A; Zanardi E; Poletti V; Cazzola M
Int J Chron Obstruct Pulmon Dis; 2015; 10():1383-92. PubMed ID: 26229457
[TBL] [Abstract][Full Text] [Related]
39. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
Punekar YS; Landis SH; Wurst K; Le H
Respir Res; 2015 Nov; 16():141. PubMed ID: 26572740
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological approach and adherence to treatment recommendations in frequently and non-frequently exacerbating COPD patients from Italy: MISTRAL - The prospective cohort, observational study.
Scalone G; Nava S; Ventrella F; Bussoli G; Catapano GA; Pennisi A; Dadduzio F; Schino P; Pela R; Bartezaghi M; Morini P; Porpiglia PA; Muscianisi E;
Pulm Pharmacol Ther; 2018 Dec; 53():68-77. PubMed ID: 30193866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
